Both in Biotechnology
Coherus Oncology vs Protara Therapeutics
Over the past year CHRS returned −53.2% and TARA returned −52.9%; their daily moves had a correlation of 0.27.
CHRS −53.2% TARA −52.9%Growth of $1, one year, split-adjusted
| Metric | CHRS | TARA |
|---|---|---|
| Price | $0.7494 | $2.41 |
| Market cap | $115.8M | $142.4M |
| Today | −9.72% | −2.82% |
| 1 month | −35.4% | −10.7% |
| 6 months | −56.7% | −55.8% |
| Year to date | −47.2% | −54.8% |
| 1 year | −55.9% | −53.1% |
| Revenue growth (YoY) | +39.5% | — |
| Gross margin | 70.4% | — |
| Net margin | −144.2% | — |
| P/E (TTM) | — | — |
| Price / sales | 2.3× | — |
| Net cash | $68.1M | $142.5M |
| Dividend yield | — | — |
| Volatility (60d) | 93.2% | 49.0% |
| Short % of float | 9.5% | 11.5% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).